Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Cancers 2011, 3(3), 3169-3188; doi:10.3390/cancers3033169
Review

C-type Lectin Receptors for Tumor Eradication: Future Directions

,
 and *
Received: 3 June 2011; in revised form: 15 July 2011 / Accepted: 1 August 2011 / Published: 8 August 2011
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
View Full-Text   |   Download PDF [484 KB, updated 16 August 2011; original version uploaded 8 August 2011]   |   Browse Figure
Abstract: Dendritic cells are key regulators in directing immune responses and therefore are under extensive research for the induction of anti-tumor responses. DCs express a large array of receptors by which they scan their surroundings for recognition and uptake of pathogens. One of the receptor-families is the C-type lectins (CLR), which bind carbohydrate structures and internalize antigens upon recognition. Intracellular routing of antigen through CLR enhances loading and presentation of antigen through MHC class I and II, inducing antigen-specific CD4+ and CD8+ T-cell proliferation and skewing T-helper cells. These characteristics make CLRs very interesting targets for DC-based immunotherapy. Profound research has been done on targeting specific tumor antigens to CLR using either antibodies or the natural ligands such as glycan structures. In this review we will focus on the current data showing the potency of CLR-targeting and discuss improvements that can be achieved to enhance anti-tumor activity in the near future.
Keywords: dendritic cells; glycans; antibodies; DC-targeting; immunotherapy dendritic cells; glycans; antibodies; DC-targeting; immunotherapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Streng-Ouwehand, I.; Unger, W.W.J.; Van Kooyk, Y. C-type Lectin Receptors for Tumor Eradication: Future Directions. Cancers 2011, 3, 3169-3188.

AMA Style

Streng-Ouwehand I, Unger WWJ, Van Kooyk Y. C-type Lectin Receptors for Tumor Eradication: Future Directions. Cancers. 2011; 3(3):3169-3188.

Chicago/Turabian Style

Streng-Ouwehand, Ingeborg; Unger, Wendy W. J.; Van Kooyk, Yvette. 2011. "C-type Lectin Receptors for Tumor Eradication: Future Directions." Cancers 3, no. 3: 3169-3188.



Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert